Open AccessPotentiation of ATRA Activity in HL-60 Cells by Targeting Methylation Enzymes
Author(s) -
Ming C. Liau
Publication year - 2019
Publication title -
journal of pharmacology, pharmaceutics, and pharmacovigilance
Language(s) - English
Resource type - Journals
ISSN - 2639-5649
DOI - 10.24966/ppp-5649/100009
Subject(s) - retinoic acid , acute promyelocytic leukemia , cancer research , histone deacetylase , leukemia , retinoic acid receptor , chemistry , tretinoin , promyelocytic leukemia protein , histone , methyltransferase , long term potentiation , biochemistry , biology , methylation , receptor , dna , immunology , gene
All Trans Retinoic Acid (ATRA) is a Differentiation Inducer (DI) of Acute Promyelocytic Leukemia (APL) with proven clinical utility. Its benefits for other types of Acute Myelocytic Leukemia (AML) have been limited. In APL, ATRA targets the PML-RARA (promyelocytic leukemia/retinoic acid receptor-alpha)/DNA methyltransferase (DNMT)/Histone Deacetylase (HDAC) complex, facilitating its